BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20599715)

  • 1. cAMP-response-element-binding protein positively regulates breast cancer metastasis and subsequent bone destruction.
    Son J; Lee JH; Kim HN; Ha H; Lee ZH
    Biochem Biophys Res Commun; 2010 Jul; 398(2):309-14. PubMed ID: 20599715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
    Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231.
    Saito H; Tsunenari T; Onuma E; Sato K; Ogata E; Yamada-Okabe H
    Anticancer Res; 2005; 25(6B):3817-23. PubMed ID: 16309168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
    Yoneda T; Williams PJ; Hiraga T; Niewolna M; Nishimura R
    J Bone Miner Res; 2001 Aug; 16(8):1486-95. PubMed ID: 11499871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
    van der Pluijm G; Sijmons B; Vloedgraven H; Deckers M; Papapoulos S; Löwik C
    J Bone Miner Res; 2001 Jun; 16(6):1077-91. PubMed ID: 11393785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
    Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
    Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.
    Bendre MS; Gaddy-Kurten D; Mon-Foote T; Akel NS; Skinner RA; Nicholas RW; Suva LJ
    Cancer Res; 2002 Oct; 62(19):5571-9. PubMed ID: 12359770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway.
    Katsuno Y; Hanyu A; Kanda H; Ishikawa Y; Akiyama F; Iwase T; Ogata E; Ehata S; Miyazono K; Imamura T
    Oncogene; 2008 Oct; 27(49):6322-33. PubMed ID: 18663362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
    Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
    Deckers M; van Dinther M; Buijs J; Que I; Löwik C; van der Pluijm G; ten Dijke P
    Cancer Res; 2006 Feb; 66(4):2202-9. PubMed ID: 16489022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CREB-1 and AP-1 transcription factors JunD and Fra-2 regulate bone sialoprotein gene expression in human breast cancer cells.
    Detry C; Lamour V; Castronovo V; Bellahcène A
    Bone; 2008 Feb; 42(2):422-31. PubMed ID: 18088579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.
    Mourskaia AA; Dong Z; Ng S; Banville M; Zwaagstra JC; O'Connor-McCourt MD; Siegel PM
    Oncogene; 2009 Feb; 28(7):1005-15. PubMed ID: 19079339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTHrP regulates angiogenesis and bone resorption via VEGF expression.
    Isowa S; Shimo T; Ibaragi S; Kurio N; Okui T; Matsubara K; Hassan NM; Kishimoto K; Sasaki A
    Anticancer Res; 2010 Jul; 30(7):2755-67. PubMed ID: 20683010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor-beta in osteolytic breast cancer bone metastases.
    Guise TA; Chirgwin JM
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S32-8. PubMed ID: 14600590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
    Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
    Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T
    Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
    Kitazawa S; Kitazawa R
    J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
    Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells.
    Sierra A; Price JE; García-Ramirez M; Méndez O; López L; Fabra A
    Lab Invest; 1997 Oct; 77(4):357-68. PubMed ID: 9354770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.
    Gordon AH; O'Keefe RJ; Schwarz EM; Rosier RN; Puzas JE
    Cancer Res; 2005 Apr; 65(8):3209-17. PubMed ID: 15833852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.